(SAN) Sanofi - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0000120578
Stock:
Total Rating 39
Risk 88
Buy Signal -0.25
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | -7.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.93 |
| Alpha | -29.85 |
| Character TTM | |
|---|---|
| Beta | 0.338 |
| Beta Downside | 0.332 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| CAGR/Max DD | 0.03 |
EPS (Earnings per Share)
Revenue
Description: SAN Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for a natural killer cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, which is used for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 10.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.90 > 1.0 |
| NWC/Revenue: 4.48% < 20% (prev 29.53%; Δ -25.05% < -1%) |
| CFO/TA 0.16 > 3% & CFO 20.32b > Net Income 10.62b |
| Net Debt (14.14b) to EBITDA (11.07b): 1.28 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.22b) vs 12m ago -2.65% < -2% |
| Gross Margin: 71.74% > 18% (prev 0.70%; Δ 7104 % > 0.5%) |
| Asset Turnover: 44.87% > 50% (prev 34.24%; Δ 10.64% > 0%) |
| Interest Coverage Ratio: 13.98 > 6 (EBITDA TTM 11.07b / Interest Expense TTM 563.0m) |
Altman Z'' 3.58
| A: 0.02 (Total Current Assets 30.95b - Total Current Liabilities 28.35b) / Total Assets 126.81b |
| B: 0.53 (Retained Earnings 66.88b / Total Assets 126.81b) |
| C: 0.06 (EBIT TTM 7.87b / Avg Total Assets 129.80b) |
| D: 1.26 (Book Value of Equity 69.32b / Total Liabilities 55.10b) |
| Altman-Z'' Score: 3.58 = A |
Beneish M -3.65
| DSRI: 0.03 (Receivables 397.0m/10.63b, Revenue 58.25b/45.47b) |
| GMI: 0.98 (GM 71.74% / 70.04%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 1.28 (Revenue 58.25b / 45.47b) |
| TATA: -0.08 (NI 10.62b - CFO 20.32b) / TA 126.81b) |
| Beneish M-Score: -3.65 (Cap -4..+1) = AAA |
What is the price of SAN shares?
As of February 28, 2026, the stock is trading at EUR 82.20 with a total of 3,455,733 shares traded.
Over the past week, the price has changed by +3.29%, over one month by +3.07%, over three months by -4.15% and over the past year by -18.14%.
Over the past week, the price has changed by +3.29%, over one month by +3.07%, over three months by -4.15% and over the past year by -18.14%.
Is SAN a buy, sell or hold?
Sanofi has no consensus analysts rating.
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 98.5 | 19.8% |
| Analysts Target Price | - | - |
SAN Fundamental Data Overview February 28, 2026
Market Cap USD = 115.56b (97.67b EUR * 1.1832 EUR.USD)
P/E Trailing = 20.0695
P/E Forward = 10.1317
P/S = 2.0906
P/B = 1.5108
P/EG = 0.7851
Revenue TTM = 58.25b EUR
EBIT TTM = 7.87b EUR
EBITDA TTM = 11.07b EUR
Long Term Debt = 14.25b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.61b EUR (from shortTermDebt, last quarter)
Debt = 21.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.14b EUR (from netDebt column, last quarter)
Enterprise Value = 111.80b EUR (97.67b + Debt 21.80b - CCE 7.66b)
Interest Coverage Ratio = 13.98 (Ebit TTM 7.87b / Interest Expense TTM 563.0m)
EV/FCF = 6.88x (Enterprise Value 111.80b / FCF TTM 16.25b)
FCF Yield = 14.54% (FCF TTM 16.25b / Enterprise Value 111.80b)
FCF Margin = 27.90% (FCF TTM 16.25b / Revenue TTM 58.25b)
Net Margin = 18.22% (Net Income TTM 10.62b / Revenue TTM 58.25b)
Gross Margin = 71.74% ((Revenue TTM 58.25b - Cost of Revenue TTM 16.46b) / Revenue TTM)
Gross Margin QoQ = 69.80% (prev 74.09%)
Tobins Q-Ratio = 0.88 (Enterprise Value 111.80b / Total Assets 126.81b)
Interest Expense / Debt = -0.43% (Interest Expense -93.0m / Debt 21.80b)
Taxrate = 14.11% (332.0m / 2.35b)
NOPAT = 6.76b (EBIT 7.87b * (1 - 14.11%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.31 (Debt 21.80b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.28 (Net Debt 14.14b / EBITDA 11.07b)
Debt / FCF = 0.87 (Net Debt 14.14b / FCF TTM 16.25b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.18% (Net Income 10.62b / Total Assets 126.81b)
RoE = 14.71% (Net Income TTM 10.62b / Total Stockholder Equity 72.18b)
RoCE = 9.11% (EBIT 7.87b / Capital Employed (Equity 72.18b + L.T.Debt 14.25b))
RoIC = 7.37% (NOPAT 6.76b / Invested Capital 91.72b)
WACC = 5.79% (E(97.67b)/V(119.46b) * Re(7.16%) + D(21.80b)/V(119.46b) * Rd(-0.43%) * (1-Tc(0.14)))
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 88.43% ; FCFF base≈15.02b ; Y1≈18.53b ; Y5≈31.55b
[DCF] Fair Price = 749.2 (EV 918.77b - Net Debt 14.14b = Equity 904.63b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -22.25 | EPS CAGR: -6.13% | SUE: 0.40 | # QB: 0
Revenue Correlation: 36.76 | Revenue CAGR: 25.75% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.77 | Chg7d=+0.004 | Chg30d=+0.056 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=8.38 | Chg7d=+0.014 | Chg30d=-0.015 | Revisions Net=+3 | Growth EPS=+7.0% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=8.91 | Chg7d=+0.003 | Chg30d=-0.032 | Revisions Net=-2 | Growth EPS=+6.4% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = -1.7% (Analyst 1.3% - Implied 3.0%)
P/E Trailing = 20.0695
P/E Forward = 10.1317
P/S = 2.0906
P/B = 1.5108
P/EG = 0.7851
Revenue TTM = 58.25b EUR
EBIT TTM = 7.87b EUR
EBITDA TTM = 11.07b EUR
Long Term Debt = 14.25b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.61b EUR (from shortTermDebt, last quarter)
Debt = 21.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.14b EUR (from netDebt column, last quarter)
Enterprise Value = 111.80b EUR (97.67b + Debt 21.80b - CCE 7.66b)
Interest Coverage Ratio = 13.98 (Ebit TTM 7.87b / Interest Expense TTM 563.0m)
EV/FCF = 6.88x (Enterprise Value 111.80b / FCF TTM 16.25b)
FCF Yield = 14.54% (FCF TTM 16.25b / Enterprise Value 111.80b)
FCF Margin = 27.90% (FCF TTM 16.25b / Revenue TTM 58.25b)
Net Margin = 18.22% (Net Income TTM 10.62b / Revenue TTM 58.25b)
Gross Margin = 71.74% ((Revenue TTM 58.25b - Cost of Revenue TTM 16.46b) / Revenue TTM)
Gross Margin QoQ = 69.80% (prev 74.09%)
Tobins Q-Ratio = 0.88 (Enterprise Value 111.80b / Total Assets 126.81b)
Interest Expense / Debt = -0.43% (Interest Expense -93.0m / Debt 21.80b)
Taxrate = 14.11% (332.0m / 2.35b)
NOPAT = 6.76b (EBIT 7.87b * (1 - 14.11%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.31 (Debt 21.80b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.28 (Net Debt 14.14b / EBITDA 11.07b)
Debt / FCF = 0.87 (Net Debt 14.14b / FCF TTM 16.25b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.18% (Net Income 10.62b / Total Assets 126.81b)
RoE = 14.71% (Net Income TTM 10.62b / Total Stockholder Equity 72.18b)
RoCE = 9.11% (EBIT 7.87b / Capital Employed (Equity 72.18b + L.T.Debt 14.25b))
RoIC = 7.37% (NOPAT 6.76b / Invested Capital 91.72b)
WACC = 5.79% (E(97.67b)/V(119.46b) * Re(7.16%) + D(21.80b)/V(119.46b) * Rd(-0.43%) * (1-Tc(0.14)))
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 88.43% ; FCFF base≈15.02b ; Y1≈18.53b ; Y5≈31.55b
[DCF] Fair Price = 749.2 (EV 918.77b - Net Debt 14.14b = Equity 904.63b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -22.25 | EPS CAGR: -6.13% | SUE: 0.40 | # QB: 0
Revenue Correlation: 36.76 | Revenue CAGR: 25.75% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.77 | Chg7d=+0.004 | Chg30d=+0.056 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=8.38 | Chg7d=+0.014 | Chg30d=-0.015 | Revisions Net=+3 | Growth EPS=+7.0% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=8.91 | Chg7d=+0.003 | Chg30d=-0.032 | Revisions Net=-2 | Growth EPS=+6.4% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = -1.7% (Analyst 1.3% - Implied 3.0%)